Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.50 |
| ▸ | PPARG | P37231 | 5/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948895 | 1.00 | PPARA (0.50) | PPARAPPARGACEPPARDAPP | |
| SCHEMBL645778 | 1.00 | PPARA (0.50) | PPARAPPARGACEPPARDAPP | |
| SCHEMBL6192765 | 0.84 | PPARA (0.47) | PPARAPPARGACEPPARDAPP | |
| SCHEMBL15620871 | 0.83 | ACE (0.46) | PPARAPPARGACEPPARDAPP | |
| SCHEMBL21776098 | 0.83 | CTSS (0.46) | PPARAPPARGACEPPARDAPP | |
| SCHEMBL15620873 | 0.83 | ACE (0.46) | PPARAPPARGACEPPARDAPP | |
| SCHEMBL22687236 | 0.83 | PPARA (0.44) | PPARAPPARGACEPPARDAPP | |
| SCHEMBL22687240 | 0.83 | PPARA (0.44) | PPARAPPARGACEPPARDAPP | |
| SCHEMBL4072618 | 0.83 | AAK1 (0.45) | PPARAPPARGACEPPARDAPP | |
| SCHEMBL1739279 | 0.83 | AAK1 (0.45) | PPARAPPARGACEPPARDAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10786580-B2 | Cholecystokinin 2 receptor targeted NIR imaging and use thereof | On Target Laboratories, LLC (US) | 2020-09-29 | — | — | US | disclosed |
| US-10500286-B2 | CCK2R-drug conjugates | ENDOCYTE, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180071408-A1 | CHOLECYSTOKININ 2 RECEPTOR TARGETED NIR IMAGING AND USE THEREOF | On Target Laboratories, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2018049129-A1 | CHOLECYSTOKININ 2 RECEPTOR TARGETED NIR IMAGING AND USE THEREOF | On Target Laboratories, LLC (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2017030859-A1 | CCK2R-DRUG CONJUGATES | ENDOCYTE, INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20100144715-A1 | Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2010-06-10 | — | — | US | disclosed |
| US-7432379-B2 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2008106077-A1 | SUBSTITUTED BENZODIAZEPINONES, BENZOXAZEPINONES AND BENZOTHIAZEPINONES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-7417152-B2 | 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-1085014-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | Zeria Pharmaceutical Co., Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071408-A1 | CHOLECYSTOKININ 2 RECEPTOR TARGETED NIR IMAGING AND USE THEREOF | CCKAR, CCKBR, GRPR | PPARA 1966/4885PPARG 1273/4885ACE 4471/4885 |
| US-10786580-B2 | Cholecystokinin 2 receptor targeted NIR imaging and use thereof | CCKAR, CCKBR, GRPR | PPARA 1966/4885PPARG 1273/4885ACE 4471/4885 |
| US-20100144715-A1 | Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers | TRPV1, TRPV4, CACNA1B | PPARA 1985/4885PPARG 1142/4885ACE 2558/4885 |
| US-10500286-B2 | CCK2R-drug conjugates | CCKAR, CCKBR, GIPR | PPARA 1746/4885PPARG 1236/4885ACE 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.